Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Pretty weak financial results growth rate 6.9% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (16.7%)
  • Dividend yield for the last twelve months 4.3%
  • Free cash flow yield 8.0% (LTM)
  • Share price is 47.8% higher than minimum and 13.9% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (10.4x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (-1.6%)58.61
year average price 58.93  


year start price 45.94 2025-11-20

min close price 45.94 2025-11-20

max close price 68.09 2026-09-03

current price 58.57 2026-11-19
Common stocks: 2 044 085 831

Dividend Yield:  4.3%
FCF Yield LTM: 8.0%
EV / LTM EBITDA: 10.4x
EV / EBITDA annualized: 9.3x
Last revenue growth (y/y):  +6.9%
Last growth of EBITDA (y/y):  +6.8%
Historical revenue growth:  +3.7%
Historical growth of EBITDA:  +29.7%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 119 804
Net Debt ($m): 30 296
EV (Enterprise Value): 150 100
EBITDA LTM ($m): 14 377
EV / LTM EBITDA: 10.4x
Price to Book: 6.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-06seekingalpha.com

Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026

2026-02-05youtube.com

Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade

2026-02-05seekingalpha.com

Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript

2026-02-05zacks.com

Weekly Jobless Claims Exceed Expectations

2026-02-05zacks.com

Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates

2026-02-05zacks.com

Jobless Claims Pop Up a Bit, Major Morning for Earnings

2026-02-05wsj.com

Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth

2026-02-05reuters.com

Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off

2026-02-03zacks.com

Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?

2026-02-02zacks.com

Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data